Assessing and minimizing the risk of percutaneous coronary intervention in patients with chronic kidney disease

References

• Gruentzig AR, Myler RK, Hanna ES, et al. Coronary transluminal angioplasty. Circulation. 1977;56(4):84-84.
   Google Scholar
• Tonelli M, Muntner P, Lloyd A, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet Lond Engl. 2012;380:807–814.
   PubMed Web of Science ®Google Scholar
• Stevens PE, Levin A. Kidney disease: improving global outcomes chronic kidney disease guideline development work group members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158:825–830.
   PubMed Web of Science ®Google Scholar
• Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.
   PubMed Web of Science ®Google Scholar
• Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification Diet Renal Disease Study Group Ann Intern Med. 1999;130:461–470.
   Google Scholar
• Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247–254.
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–612.
   PubMed Web of Science ®Google Scholar
• George C, Mogueo A, Okpechi I, et al. Chronic kidney disease in low-income to middle-income countries: the case for increased screening. BMJ Glob. Health [Internet]. 2017;2. [cited 2018 Jun 29]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584488/
   Google Scholar
• Palmerini T, Marzocchi A, Tamburino C, et al. Two-year clinical outcome with drug-eluting stents versus bare-metal stents in a real-world registry of unprotected left main coronary artery stenosis from the Italian Society of Invasive Cardiology. Am J Cardiol. 2008;102:1463–1468.
   PubMed Web of Science ®Google Scholar
• Mehran R, Pocock SJ, Stone GW, et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J. 2009;30:1457–1466.
   PubMed Web of Science ®Google Scholar
• Spinler SA, Mahaffey KW, Gallup D, et al. Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGY. Int J Cardiol. 2010;144:36–41.
   PubMed Web of Science ®Google Scholar
• Saltzman AJ, Stone GW, Claessen BE, et al. Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. JACC Cardiovasc Interv. 2011;4:1011–1019.
   PubMedGoogle Scholar
• Baber U, Stone GW, Weisz G, et al. Coronary plaque composition, morphology, and outcomes in patients with and without chronic kidney disease presenting with acute coronary syndromes. JACC Cardiovasc Imaging. 2012;5:S53–61.
   PubMed Web of Science ®Google Scholar
• Sederholm Lawesson S, Alfredsson J, Szummer K, et al. Prevalence and prognostic impact of chronic kidney disease in STEMI from a gender perspective: data from the SWEDEHEART register, a large Swedish prospective cohort. BMJ Open. 2015;5:e008188.
   PubMed Web of Science ®Google Scholar
• Baber U, Mehran R, Kirtane AJ, et al. Prevalence and impact of high platelet reactivity in chronic kidney disease: results from the assessment of dual antiplatelet therapy with drug-eluting stents registry. Circ Cardiovasc Interv. 2015;8:e001683.
   PubMed Web of Science ®Google Scholar
• Baber U, Giustino G, Sartori S, et al. Effect of chronic kidney disease in women undergoing percutaneous coronary intervention with drug-eluting stents: a patient-level pooled analysis of randomized controlled trials. JACC Cardiovasc Interv. 2016;9:28–38.
   PubMedGoogle Scholar
• Baber U, Chandrasekhar J, Sartori S, et al. Associations between chronic kidney disease and outcomes with use of prasugrel versus clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the PROMETHEUS study. JACC Cardiovasc Interv. 2017;10:2017–2025.
   PubMedGoogle Scholar
• Heer T, Hochadel M, Schmidt K, et al. Sex differences in percutaneous coronary intervention-insights from the coronary angiography and PCI registry of the German society of cardiology. J Am Heart Assoc. 2017;6(3). pii: e004972.
   PubMedGoogle Scholar
• Kwok CS, Rao SV, Potts JE, et al. Burden of 30-day readmissions after percutaneous coronary intervention in 833,344 patients in the United States: predictors, causes, and cost: insights from the nationwide readmission database. JACC Cardiovasc Interv. 2018;11:665–674.
   PubMedGoogle Scholar
• Baber U, Li SX, Pinnelas R, et al. Incidence, patterns, and impact of dual antiplatelet therapy cessation among patients with and without chronic kidney disease undergoing percutaneous coronary intervention: results from the PARIS registry (patterns of non-adherence to anti-platelet regimens in stented patients). Circ Cardiovasc Interv. 2018;11:e006144.
   PubMed Web of Science ®Google Scholar
• Chamaria S, Bhatheja S, Vengrenyuk Y, et al. Prognostic relation between severity of diabetes mellitus (on or off insulin) ± chronic kidney disease with cardiovascular risk after percutaneous coronary intervention. Am J Cardiol. 2018;121:168–176.
   PubMed Web of Science ®Google Scholar
• Bakris GL. Lipid disorders in uremia and dialysis. Contrib Nephrol. 2012;178:100–105.
   PubMed Web of Science ®Google Scholar
• Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. The Lancet. 2013;382:339–352.
   PubMed Web of Science ®Google Scholar
• Sibal L, Agarwal SC, Home PD, et al. The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. Curr Cardiol Rev. 2010;6:82–90.
   PubMedGoogle Scholar
• Aldámiz-Echevarría L, Andrade F. Asymmetric dimethylarginine, endothelial dysfunction and renal disease. Int J Mol Sci. 2012;13:11288–11311.
   PubMed Web of Science ®Google Scholar
• Pacurari M, Kafoury R, Tchounwou PB, et al. The renin-angiotensin-aldosterone system in vascular inflammation and remodeling. Int J Inflamm [Internet]. 2014;2014. cited 2018 Jul 2. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3997861/
   Google Scholar
• Schiffrin EL, Lipman ML, Mann JFE. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007;116:85–97.
   PubMed Web of Science ®Google Scholar
• Hruska K, Mathew S, Lund R, et al. Cardiovascular risk factors in chronic kidney disease: does phosphate qualify? Kidney Int. 2011;79121:S9–S13.
   PubMedGoogle Scholar
• Madhavan MV, Tarigopula M, Mintz GS, et al. Coronary artery calcification: pathogenesis and prognostic implications. J Am Coll Cardiol. 2014;63:1703–1714.
   PubMed Web of Science ®Google Scholar
• Park D-W, Kim Y-H, Yun S-C, et al. Frequency, causes, predictors, and clinical significance of peri-procedural myocardial infarction following percutaneous coronary intervention. Eur Heart J. 2013;34:1662–1669.
   PubMed Web of Science ®Google Scholar
• Zeitouni M, Silvain J, Guedeney P, et al. Periprocedural myocardial infarction and injury in elective coronary stenting. Eur Heart J. 2018;39:1100–1109.
   PubMed Web of Science ®Google Scholar
• Lutz J, Menke J, Sollinger D, et al. Haemostasis in chronic kidney disease. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc Eur Ren Assoc. 2014;29:29–40.
   PubMed Web of Science ®Google Scholar
• Wańha W, Kawecki D, Roleder T, et al. Long-term percutaneous coronary intervention outcomes of patients with chronic kidney disease in the era of second-generation drug-eluting stents. Cardiorenal Med. 2017;7:85–95.
   PubMed Web of Science ®Google Scholar
• Baber U, Mehran R, Giustino G, et al. Coronary thrombosis and major bleeding after PCI with drug-eluting stents: risk scores from PARIS. J Am Coll Cardiol. 2016;67:2224–2234.
   PubMed Web of Science ®Google Scholar
• Costa F, van Klaveren D, James S, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet Lond Engl. 2017;389:1025–1034.
   PubMed Web of Science ®Google Scholar
• Subherwal S, Bach RG, Chen AY, et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. Circulation. 2009;119:1873–1882.
   PubMed Web of Science ®Google Scholar
• Urban P, Meredith IT, Abizaid A, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med. 2015;373:2038–2047.
   PubMed Web of Science ®Google Scholar
• Shavadia JS, Southern DA, James MT, et al. Kidney function modifies the selection of treatment strategies and long-term survival in stable ischemic heart disease: insights from the Alberta Provincial Project for Outcomes Assessment in Coronary Heart Disease (APPROACH) Registry. Eur Heart J Qual Care Clin Outcomes. 2017.
   Google Scholar
• Smilowitz NR, Gupta N, Guo Y, et al. Management and outcomes of acute myocardial infarction in patients with chronic kidney disease. Int J Cardiol. 2017;227:1–7.
   PubMed Web of Science ®Google Scholar
• Huang HD, Alam M, Hamzeh I, et al. Patients with severe chronic kidney disease benefit from early revascularization after acute coronary syndrome. Int J Cardiol. 2013;168:3741–3746.
   PubMed Web of Science ®Google Scholar
• Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44:1393–1399.
   PubMed Web of Science ®Google Scholar
• Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the second international consensus conference of the Acute Dialysis Quality Initiative (ADQI) group. Crit Care Lond Engl. 2004;8:R204–212.
   PubMed Web of Science ®Google Scholar
• Mehta RL, Kellum JA, Shah SV, et al. Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care Lond Engl. 2007;11:R31.
   PubMed Web of Science ®Google Scholar
• McCullough PA, Choi JP, Feghali GA, et al. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2016;68:1465–1473.
   PubMed Web of Science ®Google Scholar
• Heyman SN, Rosen S, Rosenberger C. Renal parenchymal hypoxia, hypoxia adaptation, and the pathogenesis of radiocontrast nephropathy. Clin J Am Soc Nephrol CJASN. 2008;3:288–296.
   PubMed Web of Science ®Google Scholar
• Tsai TT, Patel UD, Chang TI, et al. Contemporary incidence, predictors, and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the NCDR cath-PCI registry. JACC Cardiovasc Interv. 2014;7:1–9.
   PubMed Web of Science ®Google Scholar
• Weisbord SD, Palevsky PM. Contrast-induced acute kidney injury: short- and long-term implications. Semin Nephrol. 2011;31:300–309.
   PubMed Web of Science ®Google Scholar
• Silvain J, Nguyen LS, Spagnoli V, et al. Contrast-induced acute kidney injury and mortality in ST elevation myocardial infarction treated with primary percutaneous coronary intervention. Heart. 2018;104(9):767-772.
   Google Scholar
• Brown JR, DeVries JT, Piper WD, et al. Serious renal dysfunction after percutaneous coronary interventions can be predicted. Am Heart J. 2008;155:260–266.
   PubMed Web of Science ®Google Scholar
• Murakami R, Kumita S, Hayashi H, et al. Anemia and the risk of contrast-induced nephropathy in patients with renal insufficiency undergoing contrast-enhanced MDCT. Eur J Radiol. 2013;82:e521–524.
   PubMed Web of Science ®Google Scholar
• Erley C. Concomitant drugs with exposure to contrast media. Kidney Int Suppl. 2006;(100):S20-4.
   Google Scholar
• Bartholomew BA, Harjai KJ, Dukkipati S, et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol. 2004;93:1515–1519.
   PubMed Web of Science ®Google Scholar
• Gurm HS, Seth M, Kooiman J, et al. A novel tool for reliable and accurate prediction of renal complications in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol. 2013;61:2242–2248.
   PubMed Web of Science ®Google Scholar
• Tsai TT, Patel UD, Chang TI, et al. Validated contemporary risk model of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the National Cardiovascular Data Registry Cath-PCI Registry. J Am Heart Assoc. 2014;3:e001380.
   PubMed Web of Science ®Google Scholar
• Gao Y, Li D, Cheng H, et al. Derivation and validation of a risk score for contrast-induced nephropathy after cardiac catheterization in Chinese patients. Clin Exp Nephrol. 2014;18:892–898.
   PubMed Web of Science ®Google Scholar
• Andò G, Morabito G, de Gregorio C, et al. Age, glomerular filtration rate, ejection fraction, and the AGEF score predict contrast-induced nephropathy in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv. 2013;82:878–885.
   PubMed Web of Science ®Google Scholar
• Capodanno D, Ministeri M, Dipasqua F, et al. Risk prediction of contrast-induced nephropathy by ACEF score in patients undergoing coronary catheterization. J Cardiovasc Med Hagerstown Md. 2016;17:524–529.
   PubMed Web of Science ®Google Scholar
• Briguori C, Visconti G, Rivera NV, et al. Cystatin C and contrast-induced acute kidney injury. Circulation. 2010;121:2117–2122.
   PubMed Web of Science ®Google Scholar
• Angeli F, Verdecchia P, Savonitto S, et al. Cystatin C and risk of mortality among patients undergoing percutaneous coronary intervention. EuroIntervention J Eur Collab Work Group Interv Cardiol Eur Soc Cardiol. 2015;11:757–764.
   Google Scholar
• S-Q S, Zhang T, Ding D, et al. Circulating microRNA-188, −30a, and −30e as early biomarkers for contrast-induced acute kidney injury. J Am Heart Assoc. 2016;5(8).
   Web of Science ®Google Scholar
• Nusca A, Miglionico M, Proscia C, et al. Early prediction of contrast-induced acute kidney injury by a “bedside” assessment of neutrophil gelatinase-associated lipocalin during elective percutaneous coronary interventions. PloS One. 2018;13:e0197833.
   PubMed Web of Science ®Google Scholar
• Wybraniec MT, Mizia-Stec K. Renalase and biomarkers of contrast-induced acute kidney injury. Cardiorenal Med. 2015;6:25–36.
   PubMed Web of Science ®Google Scholar
• Duan S-B, Liu G-L, Yu Z-Q, et al. Urinary KIM-1, IL-18 and Cys-c as early predictive biomarkers in gadolinium-based contrast-induced nephropathy in the elderly patients. Clin Nephrol. 2013;80:349–354.
   PubMed Web of Science ®Google Scholar
• Annamalai SK, Kapur NK. Contrast induced nephropathy after coronary or vascular intervention: more biomarkers than answers. Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv. 2018;91:1192–1193.
   PubMed Web of Science ®Google Scholar
• Windecker S, Kolh P, Alfonso F, et al. Authors/Task Force members. ESC/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541–2619.
   PubMed Web of Science ®Google Scholar
• Brar SS, Aharonian V, Mansukhani P, et al. Haemodynamic-guided fluid administration for the prevention of contrast-induced acute kidney injury: the POSEIDON randomised controlled trial. Lancet Lond Engl. 2014;383:1814–1823.
   PubMed Web of Science ®Google Scholar
• Qian G, Fu Z, Guo J, et al. Prevention of contrast-induced nephropathy by central venous pressure-guided fluid administration in chronic kidney disease and congestive heart failure patients. JACC Cardiovasc Interv. 2016;9:89–96.
   PubMed Web of Science ®Google Scholar
• Stevens MA, McCullough PA, Tobin KJ, et al. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. study. Prevention of radiocontrast induced nephropathy clinical evaluation. J Am Coll Cardiol. 1999;33:403–411.
   PubMed Web of Science ®Google Scholar
• Briguori C, Visconti G, Ricciardelli B, et al. Renal insufficiency following contrast media administration trial II (REMEDIAL II): renalGuard system in high-risk patients for contrast-induced acute kidney injury: rationale and design. EuroIntervention J Eur Collab Work Group Interv Cardiol Eur Soc Cardiol. 2011;6:1117–1122,7.
   Google Scholar
• Briguori C, Visconti G, Focaccio A, et al. Renal insufficiency after contrast media administration trial II (REMEDIAL II): renalGuard system in high-risk patients for contrast-induced acute kidney injury. Circulation. 2011;124:1260–1269.
   PubMed Web of Science ®Google Scholar
• Putzu A, Boscolo Berto M, Belletti A, et al. Prevention of contrast-induced acute kidney injury by furosemide with matched hydration in patients undergoing interventional procedures: a systematic review and meta-analysis of randomized trials. JACC Cardiovasc Interv. 2017;10:355–363.
   PubMed Web of Science ®Google Scholar
• Nijssen EC, Rennenberg RJ, Nelemans PJ, et al. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet Lond Engl. 2017;389:1312–1322.
   PubMed Web of Science ®Google Scholar
• Schwarz V, Heine GH, Böhm M, et al. Hydration and contrast-induced kidney injury. The Lancet. 2017;390:452.
   PubMedGoogle Scholar
• Seeliger E, Lenhard DC, Persson PB. Contrast media viscosity versus osmolality in kidney injury: lessons from animal studies. BioMed Res Int. 2014;2014:358136.
   PubMed Web of Science ®Google Scholar
• Bangalore S, Briguori C. Preventive strategies for contrast-induced acute kidney injury: and the winner is…. Circ Cardiovasc Interv. 2017;10:e005262.
   PubMed Web of Science ®Google Scholar
• Liu Y, Li H, Chen S, et al. Excessively high hydration volume may not be associated with decreased risk of contrast-induced acute kidney injury after percutaneous coronary intervention in patients with renal insufficiency. J Am Heart Assoc. 2016;5(6). pii: e003171.
   Google Scholar
• Tepel M, van der Giet M, Schwarzfeld C, et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000;343:180–184.
   PubMed Web of Science ®Google Scholar
• Marenzi G, Assanelli E, Marana I, et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med. 2006;354:2773–2782.
   PubMed Web of Science ®Google Scholar
• Brar SS, Hiremath S, Dangas G, et al. Sodium bicarbonate for the prevention of contrast induced-acute kidney injury: a systematic review and meta-analysis. Clin J Am Soc Nephrol CJASN. 2009;4:1584–1592.
   PubMed Web of Science ®Google Scholar
• Giacoppo D, Gargiulo G, Buccheri S, et al. Preventive strategies for contrast-induced acute kidney injury in patients undergoing percutaneous coronary procedures: evidence from a hierarchical Bayesian network meta-analysis of 124 trials and 28 240 patients. Circ Cardiovasc Interv. 2017;10.
   PubMed Web of Science ®Google Scholar
• Weisbord SD, Gallagher M, Jneid H, et al. Outcomes after angiography with sodium bicarbonate and acetylcysteine. N Engl J Med. 2018;378:603–614.
   PubMed Web of Science ®Google Scholar
• Antonopoulos AS, Margaritis M, Lee R, et al. Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des. 2012;18:1519–1530.
   PubMed Web of Science ®Google Scholar
• Leoncini M, Toso A, Maioli M, et al. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: results from the PRATO-ACS study (protective effect of rosuvastatin and antiplatelet therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome). J Am Coll Cardiol. 2014;63:71–79.
   PubMed Web of Science ®Google Scholar
• Alexander KP, Chen AY, Roe MT, et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA. 2005;294:3108–3116.
   PubMed Web of Science ®Google Scholar
• Ibanez B, James S, Agewall S, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-177.
   Google Scholar
• Washam JB, Kaltenbach LA, Wojdyla DM, et al. Anticoagulant use among patients with end-stage renal disease undergoing percutaneous coronary intervention: an analysis from the national cardiovascular data registry. Circ Cardiovasc Interv. 2018;11:e005628.
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Frigoli E, Leonardi S, et al. Bivalirudin or unfractionated heparin in acute coronary syndromes. N Engl J Med. 2015;373:997–1009.
   PubMed Web of Science ®Google Scholar
• Erlinge D, Omerovic E, Fröbert O, et al. Bivalirudin versus heparin monotherapy in myocardial infarction. N Engl J Med. 2017;377:1132–1142.
   PubMed Web of Science ®Google Scholar
• James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the platelet inhibition and patient outcomes (PLATO) trial. Circulation. 2010;122:1056–1067.
   PubMed Web of Science ®Google Scholar
• McCullough PA, Bertrand ME, Brinker JA, et al. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media. J Am Coll Cardiol. 2006;48:692–699.
   PubMed Web of Science ®Google Scholar
• Wessely R, Koppara T, Bradaric C, et al. Choice of contrast medium in patients with impaired renal function undergoing percutaneous coronary intervention. Circ Cardiovasc Interv. 2009;2:430–437.
   PubMed Web of Science ®Google Scholar
• Laskey WK, Jenkins C, Selzer F, et al. Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention. J Am Coll Cardiol. 2007;50:584–590.
   PubMed Web of Science ®Google Scholar
• Marenzi G, Assanelli E, Campodonico J, et al. Contrast volume during primary percutaneous coronary intervention and subsequent contrast-induced nephropathy and mortality. Ann Intern Med. 2009;150:170–177.
   PubMed Web of Science ®Google Scholar
• Andò G, de Gregorio C, Morabito G, et al. Renal function-adjusted contrast volume redefines the baseline estimation of contrast-induced acute kidney injury risk in patients undergoing primary percutaneous coronary intervention. Circ Cardiovasc Interv. 2014;7:465–472.
   PubMed Web of Science ®Google Scholar
• Prasad A, Ortiz-Lopez C, Kaye DM, et al. The use of the AVERT system to limit contrast volume administration during peripheral angiography and intervention. Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv. 2015;86:1228–1233.
   PubMed Web of Science ®Google Scholar
• Corcione N, Biondi-Zoccai G, Ferraro P, et al. Contrast minimization with the new-generation dyevert plus system for contrast reduction and real-time monitoring during coronary and peripheral procedures: first experience. J Invasive Cardiol. 2017;29:259–262.
   PubMed Web of Science ®Google Scholar
• Desch S, Fuernau G, Pöss J, et al. Impact of a novel contrast reduction system on contrast savings in coronary angiography - the dyevert randomised controlled trial. Int J Cardiol. 2018;257:50–53.
   PubMed Web of Science ®Google Scholar
• Mehran R, Faggioni M, Chandrasekhar J, et al. Effect of a contrast modulation system on contrast media use and the rate of acute kidney injury after coronary angiography. Jacc Cardiovasc. Interv. 2018;11:1601–1610.
   PubMed Web of Science ®Google Scholar
• Ohno Y, Maekawa Y, Miyata H, et al. Impact of periprocedural bleeding on incidence of contrast-induced acute kidney injury in patients treated with percutaneous coronary intervention. J Am Coll Cardiol. 2013;62:1260–1266.
   PubMed Web of Science ®Google Scholar
• Andò G, Cortese B, Russo F, et al. Acute kidney injury after radial or femoral access for invasive acute coronary syndrome management: AKI-MATRIX. J Am Coll Cardiol. 2017 May 11. pii: S0735-1097(17)36897-3.
   PubMedGoogle Scholar
• Flaherty MP, Pant S, Patel SV, et al. Hemodynamic support with a microaxial percutaneous left ventricular assist device (impella) protects against acute kidney injury in patients undergoing high-risk percutaneous coronary intervention. Circ Res. 2017;120:692–700.
   PubMed Web of Science ®Google Scholar
• Mariani J, Guedes C, Soares P, et al. Intravascular ultrasound guidance to minimize the use of iodine contrast in percutaneous coronary intervention: the MOZART (minimizing cOntrast utiliZation with IVUS guidance in coRonary angioplasTy) randomized controlled trial. JACC Cardiovasc Interv. 2014;7:1287–1293.
   PubMedGoogle Scholar
• Ali ZA, Karimi Galougahi K, Nazif T, et al. Imaging- and physiology-guided percutaneous coronary intervention without contrast administration in advanced renal failure: a feasibility, safety, and outcome study. Eur Heart J. 2016;37:3090–3095.
   PubMedGoogle Scholar
• Dan K, Miyoshi T, Nakahama M, et al. Impact of chronic kidney disease on cardiovascular and renal events in patients undergoing percutaneous coronary intervention with everolimus-eluting stent: risk stratification with C-reactive protein. Cardiorenal Med. 2018;8:151–159.
   PubMed Web of Science ®Google Scholar
• Karimi Galougahi K, Zalewski A, Leon MB, et al. Optical coherence tomography-guided percutaneous coronary intervention in pre-terminal chronic kidney disease with no radio-contrast administration. Eur Heart J. 2016;37:1059.
   PubMedGoogle Scholar
• Azzalini L, Mitomo S, Hachinohe D, et al. Zero-contrast percutaneous coronary intervention guided by dextran-based optical coherence tomography. Can J Cardiol. 2018;34:342.e1–342.e3.
   Web of Science ®Google Scholar